Pills in Packaging

Mark Cuban Plans Low-Cost Generic Drugs With Pharma Startup

Mark Cuban is getting involved in generic drugs.

The Dallas Mavericks owner has attached his name to a company that will produce low-cost versions of expensive generic drugs. The Mark Cuban Cost Plus Drug Company pledges “to provide radical transparency” in how it prices its drugs.

The company will manufacture, distribute, and market its drugs to pharmacies and add a flat 15% margin to get wholesale prices.

The first drug to be produced is albendazole, an anti-parasitic pill that can retail for over $400 per tablet. The company plans to make and distribute the drug for about $13, charge $15 as a wholesale price and set a manufacturer’s suggested retail price of $20 per tablet, according to the company’s website.

Read more…

Covid Vaccine

N.J. Pharmaceutical Company’s COVID Vaccine Could Be A Game-Changer. Here’s Why

As the nation struggles to scale up its COVID-19 immunization rollout, another vaccine in the works could soon help bridge the gap.

The two vaccines available now — one by Pfizer/BioNTech and another by Moderna — require two doses: a priming shot and then a booster three or four weeks later, depending on which company’s injection you get.

But another vaccine on the horizon — developed by Johnson & Johnson — would require only a single dose. It could be a game-changer for distribution, which continues to drag in New Jersey and beyond.

Read more…

Doctor with Vaccine

AM-Pharma Enrolls First Patients in Covid-19 Phase III Trial

AM-Pharma has recruited first patients with Covid-19 infection and sepsis-associated acute kidney injury (SA-AKI) in an exploratory cohort of its phase III REVIVAL pivotal trial.

The phase III randomised, double-blind, placebo-controlled, two-arm, parallel-group and multi-centre study will assess safety, tolerability and clinical benefit of the company’s human recombinant alkaline phosphatase to treat patients with SA-AKI.

AM-Pharma will recruit up to 1,400 patients with SA-AKI in the main study population. The company will recruit up to 100 patients with moderate chronic kidney disease (CKD) and up to 100 patients with Covid-19 in two exploratory cohorts.

Read more…

Capitol Building

Pharma Condemns Pro-Trump ‘Thugs’ and Riots—and Backs Manufacturing Group’s Call For Consequences

Pharma executives and trade groups joined the chorus of voices condemning the pro-Trump insurrection on Capitol Hill yesterday. Speaking up on social media and issuing statements against the mob chaos—as Congress worked to certify President-elect Joseph Biden’s election—industry reps went so far as to support a call to consider removing President Donald Trump from office.

The National Association of Manufacturers (NAM)—which counts reps from Pfizer, Merck & Co., Johnson & Johnson, Eli Lilly and Mallinckrodt among its executive committee members—called for consideration of the 25th Amendment to remove Trump from office. It condemned the attacks as sedition and placed the blame squarely at his feet.
Doctor with vaccine

Vaccines Boost Big Pharma’s Image, But Won’t Change Its Ways

The development of Covid-19 vaccines in record time will not be enough to fix big pharma’s tarnished image.

In 1955, Jonas Salk, the inventor of the polio vaccine, was asked a question about who owned the patent to the drug. “Well, the people I would say,” he told a journalist. “There is no patent. Could you patent the Sun?”

The widespread availability of an affordable polio vaccine in subsequent years has almost eliminated the disease from the world, saving millions of children from paralysis and death.

A few months back, large American and European pharmaceutical companies in the race to make Covid-19 vaccines were being pushed to follow Salk’s path and keep their research in the public domain.

Read more…

Pharmaceuticals

Expect More Pharma Corporate Campaigns in 2021 As The Industry Leverages Its COVID-19 Halo

When the pandemic struck, pharma companies picked up their tools and went to work. The industry began accelerated vaccine development, scoured old and new drugs for treatment potential and rushed to create new diagnostics tests.

And, outside the lab, companies pitched in with millions of dollars for contributions of personal protective gear, donations to local community efforts such as food banks and newly launched health inequality efforts.

TV and digital campaigns during the pandemic not only reinforced the industry’s key role in mitigating the pandemic but also doubled down on showcasing its dedication to science.

Read more…

Covid Vaccine

Breakingviews – Big Pharma’s Vaccine Immunity Will Be Fleeting

LONDON (Reuters Breakingviews) – Big Pharma’s vaccine victory lap may be cut short. The industry’s triumph in dispensing inoculations less than a year after the discovery of the deadly coronavirus has partially vindicated the business models of groups like Pfizer, Moderna and AstraZeneca. But as governments took on much of the risk, pharma groups’ pricing will remain a target after the pandemic.

Riding to the world’s rescue is a welcome corrective for the battered pharmaceutical industry. In recent years the sector has grappled with bribery scandals and accusations of aggressive pricing, exemplified by Mylan’s decision to hike the price of anti-allergy injection EpiPen by 400%.

Read more…

Medical Syringe & Vaccine

Fosun Pharma To Buy 100 Million Doses of BioNTech’s COVID-19 Vaccine For Mainland China

(Reuters) -Shanghai Fosun Pharmaceutical Group Co Ltd on Wednesday said it will buy at least 100 million doses of a COVID-19 vaccine from Germany’s BioNTech SE for use in mainland China next year, if the vaccine receives approval.

The Chinese government has not announced supply deals with Western drugmakers, which instead have partnered local firms.

Fosun said it will be entitled to 60% of annual gross profit from sales of doses that it will make from imported bulk ingredients, and 65% of profit from sales of doses imported ready for use.

For the initial supply of 50 million doses, Fosun will make an advance payment to BioNTech of 250 million euros ($303.80 million) – half by Dec. 30 and the remainder after regulatory approval – the firm said in a Hong Kong stock exchange filing.

Read more…

Doctor with Vaccine

Factbox-Indian Pharma Industry’s COVID-19 Vaccine Plans

(REUTERS) – SEVERAL Indian pharmaceutical companies are working to develop or manufacture at least eight anti-COVID-19 formulations as the world’s largest producer of vaccines prepares for a massive response to the coronavirus pandemic.

India, which has itself been badly hit by the pandemic with nearly 10 million infections, the second-highest in the world, is focusing on affordable vaccines instead of the expensive messenger RNA shots of Pfizer Inc and Moderna Inc.

Here is a look at the companies that are developing or manufacturing vaccines in India:

Pharma in Protective Gear

Pharmaceuticals Rely on Biotech Firms To Discover New Drug Candidates

Local pharmaceutical companies are teaming up with biotech firms to utilize cutting-edge technologies such as liquid biopsy and deep learning to discover candidates for innovative medicines.

Boryung Pharmaceutical has been most active in joining hands with the biotech industry.

On Tuesday, the company agreed with Quantum Intelligence, an AI-using new drug developer, for joint research. The deal came just four days after Boryung and IMBDx decided to collaborate on treatment development using IMBDx’s liquid biopsy technology for cancer diagnosis.

In June, Boryung also built a partnership with Pharminogen, a novel drug developer using deep learning.

Read more…